SG11201408731WA - USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM - Google Patents

USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM

Info

Publication number
SG11201408731WA
SG11201408731WA SG11201408731WA SG11201408731WA SG11201408731WA SG 11201408731W A SG11201408731W A SG 11201408731WA SG 11201408731W A SG11201408731W A SG 11201408731WA SG 11201408731W A SG11201408731W A SG 11201408731WA SG 11201408731W A SG11201408731W A SG 11201408731WA
Authority
SG
Singapore
Prior art keywords
dihydroxyvitamin
methylene
secondary hyperparathyroidism
treat secondary
treat
Prior art date
Application number
SG11201408731WA
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Julia B Zella
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408731W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of SG11201408731WA publication Critical patent/SG11201408731WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201408731WA 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM SG11201408731WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
SG11201408731WA true SG11201408731WA (en) 2015-01-29

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408731WA SG11201408731WA (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D<sb>3</sb> TO TREAT SECONDARY HYPERPARATHYROIDISM

Country Status (19)

Country Link
US (4) US9205096B2 (enrdf_load_stackoverflow)
EP (1) EP2866811A1 (enrdf_load_stackoverflow)
JP (1) JP2015522015A (enrdf_load_stackoverflow)
KR (1) KR20150030673A (enrdf_load_stackoverflow)
CN (1) CN104394871A (enrdf_load_stackoverflow)
AU (1) AU2013281217B2 (enrdf_load_stackoverflow)
BR (1) BR112014032847A2 (enrdf_load_stackoverflow)
CA (1) CA2877680C (enrdf_load_stackoverflow)
CL (1) CL2014003565A1 (enrdf_load_stackoverflow)
CO (1) CO7240358A2 (enrdf_load_stackoverflow)
HK (1) HK1206600A1 (enrdf_load_stackoverflow)
IL (1) IL236184A0 (enrdf_load_stackoverflow)
MX (1) MX2015000076A (enrdf_load_stackoverflow)
MY (1) MY172886A (enrdf_load_stackoverflow)
NZ (1) NZ703347A (enrdf_load_stackoverflow)
RU (1) RU2666995C2 (enrdf_load_stackoverflow)
SG (1) SG11201408731WA (enrdf_load_stackoverflow)
WO (1) WO2014003849A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500119B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522015A (ja) * 2012-06-29 2015-08-03 ウイスコンシン アラムニ リサーチ ファンデーション 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用
BR112016006285B1 (pt) 2013-09-27 2022-09-06 Codexis, Inc Método implementado usando um sistema de computador, meio de armazenamento legível por computador, e, sistema
DK3049979T3 (da) 2013-09-27 2020-02-17 Codexis Inc Struktur-baseret prædiktiv konstruktion
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
JP2003528833A (ja) 2000-03-27 2003-09-30 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 腎移植体安定化用のビタミンｄ化合物
CA2416194C (en) * 2000-07-14 2009-10-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
EP1667688A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
ES2404061T3 (es) 2005-02-11 2013-05-23 Wisconsin Alumni Research Foundation 2-Metileno-19-nor-(20S-24S)-1-alfa,25-dihidroxivitamina-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
AU2010281391B2 (en) * 2009-08-03 2015-05-07 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
ES2545403T3 (es) 2010-03-23 2015-09-10 Wisconsin Alumni Research Foundation (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3
JP2015522015A (ja) * 2012-06-29 2015-08-03 ウイスコンシン アラムニ リサーチ ファンデーション 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用

Also Published As

Publication number Publication date
NZ703347A (en) 2016-05-27
RU2666995C2 (ru) 2018-09-13
US20170252360A1 (en) 2017-09-07
IL236184A0 (en) 2015-01-29
JP2015522015A (ja) 2015-08-03
ZA201500119B (en) 2017-11-29
CO7240358A2 (es) 2015-04-17
CL2014003565A1 (es) 2015-08-28
CN104394871A (zh) 2015-03-04
AU2013281217A1 (en) 2015-01-22
CA2877680C (en) 2017-08-29
US20160136184A1 (en) 2016-05-19
US20140005152A1 (en) 2014-01-02
US9717744B2 (en) 2017-08-01
US20140187522A1 (en) 2014-07-03
HK1206600A1 (en) 2016-01-15
US9205096B2 (en) 2015-12-08
AU2013281217B2 (en) 2017-03-02
CA2877680A1 (en) 2014-01-03
EP2866811A1 (en) 2015-05-06
RU2015102831A (ru) 2016-08-20
BR112014032847A2 (pt) 2017-06-27
KR20150030673A (ko) 2015-03-20
US9034853B2 (en) 2015-05-19
WO2014003849A1 (en) 2014-01-03
US10046000B2 (en) 2018-08-14
MX2015000076A (es) 2015-04-10
MY172886A (en) 2019-12-13

Similar Documents

Publication Publication Date Title
SG11201408731WA (en) USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D&lt;sb&gt;3&lt;/sb&gt; TO TREAT SECONDARY HYPERPARATHYROIDISM
PL3336097T3 (pl) Wytwarzanie niekrystalicznej postaci kwasu obetycholowego
CO7061082A2 (es) Compuestos para tratar la artrofia muscular espinal
EP2793757A4 (en) THA WITH ANATOMIC CONCENTRIC BALLS
ZA201504408B (en) Solution formulations of engineered anti-il-23p19 antibodies
PL2888639T3 (pl) Transformator rozdzielczy
RS56667B1 (sr) Kombinovane formulacije darunavira
IL229700A0 (en) Dronvir formulations
IL235802A0 (en) A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
IL237483A0 (en) Preparations for the treatment of psoriasis
PL2852582T3 (pl) Nowe analogi strigolaktonu i ich zastosowanie do zabiegu na roślinach
GB201222683D0 (en) Chemical reactor
PL2484602T5 (pl) Taśmy opasujące z surowców odnawialnych
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
PL2730279T3 (pl) Preparaty cynakalcetu o natychmiastowym uwalnianiu
PL2859647T3 (pl) Ruchoma platforma produkcji elektryczności w trybie awaryjnym lub jako skrajnej końcówki
PT2702045T (pt) Método inovador para a preparação de etravirina
IL234440A0 (en) Process for the production of nitroalcohols
SG11201406582XA (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the
GB201214053D0 (en) OO infinity radil generating plant
TH1201002015B (th) วิธีการปรับปรุงโครงสร้างของพอลิเอทธิลีน แวกซ์ โดยปฏิกิริยาโบรมิเนชัน
AP2013006750A0 (en) Pole-type distribution transformer
GB201220869D0 (en) Process for sysnthesis of C2-substitutes analogues of 1a,25-dihydroxyvitamin D3
TWM433220U (en) Self-generated power transmission mechanism for exercise equipment